StockPriceToday
Sanofi ADS (SNY)
About Sanofi ADS
Sanofi, founded through mergers of French pharmaceutical companies, has become one of the world's leading pharmaceutical companies with a diverse portfolio spanning prescription drugs, vaccines, and consumer health products. The company's global reach and comprehensive R&D capabilities position it as a major player in addressing global health challenges. SNY stock price reflects the company's diversified pharmaceutical portfolio and pipeline potential.
Under the leadership of CEO Paul Hudson, Sanofi has focused on transforming its portfolio toward higher-growth areas including immunology, oncology, and rare diseases while maintaining leadership in vaccines and diabetes care. The management team has implemented strategic initiatives to accelerate innovation and improve operational efficiency. Leadership's vision for building a focused pharmaceutical company with sustainable growth has been important for repositioning Sanofi and influencing SNY stock price performance.
Sanofi operates through multiple business units including pharmaceuticals, vaccines, and consumer healthcare, serving patients worldwide with treatments for diabetes, immunological disorders, rare diseases, and other conditions. The company's global infrastructure and R&D capabilities enable development and commercialization of innovative therapies. With an aging global population driving healthcare demand, Sanofi's diversified portfolio providing stability, and continued investment in next-generation therapies, SNY offers investors exposure to global healthcare trends through one of the world's most established pharmaceutical companies with both current revenue generation and long-term innovation potential.
SNY Stock 12 Month Chart
Latest News for SNY
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
Sanofi has increased its dividend for 31 consecutive years. That’s a fantastic track record. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That’s a compound ...
Sanofi SA SNY shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline. On Thursday, the French drugmaker with a market ...
Other Popular Stocks
ArrowMark Financial Corp. operates as a business development company providing financing solutions to middle-market companies.
Intuit Inc. provides financial management and compliance software and services for consumers, small businesses, and accounting professionals worldwide.
Outset Medical Inc. (OM) is a medical technology company developing and manufacturing dialysis machines and related products for kidney disease treatment in clinical and...